Database : MEDLINE
Search on : Lymphoma [Words]
References found : 263942 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 26395 go to page                         

  1 / 263942 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29099538
[Au] Autor:Carbone A; Gloghini A
[Ad] Address:Department of Pathology, Centro di Riferimento Oncologico Aviano (CRO), Istituto Nazionale Tumori, IRCCS, Aviano (Pordenone) - Italy.
[Ti] Title:How immunologic and genetic biomarkers impact Hodgkin lymphoma classification, diagnosis, and management: a huge potential that yet needs to be exploited.
[So] Source:Int J Biol Markers;:0, 2017 Oct 28.
[Is] ISSN:1724-6008
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:"Ne è passata di acqua sotto i ponti." It has been a long time since the diagnosis of Hodgkin lymphoma (HL) was exclusively based on the detection of typical Reed-Sternberg cells and the recognition of the characteristic morpho-histological background, as well as on the pathologist's skill. The discovery of immunologic, molecular genetic and virologic biomarkers has provided an objective contribution to the diagnosis and a scientific basis for a modern classification of HL. Recent updates have clarified the nature of the so-called nodular lymphocyte predominant HL and its link to the T-cell/histiocyte-rich large B-cell lymphomas as well as its relationship with the lymphocyte-rich subset of classical HL (CHL). Molecular virology studies assessed a role for the Epstein-Barr virus in the pathogenesis of a fraction of CHL of the general population, and virtually in all cases of CHL occurring in people infected by HIV. Finally, immunologic and genetic findings corroborated the existence of grey zone lymphomas at the edges of CHL. Overall, these advances provided additional and useful information to address the treatment of patients affected by HL.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher

  2 / 263942 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29099482
[Au] Autor:Opferman JT; Kothari A
[Ad] Address:Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
[Ti] Title:Anti-apoptotic BCL-2 family members in development.
[So] Source:Cell Death Differ;, 2017 Nov 03.
[Is] ISSN:1476-5403
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Almost 30 years ago it was first appreciated that anti-apoptotic B-cell lymphoma-2 (BCL-2) prevents the induction of apoptosis not only in malignant cells, but also in normal cellular lineages. This critical observation has rapidly evolved from merely identifying new BCL-2 family members to understanding how their biochemical interactions trigger the cell death process, and, more recently, to pharmacological inhibition of anti-apoptotic BCL-2 function in disease. Indeed, the proper regulation of apoptosis is important in many aspects of life including development, homeostasis, and disease biology. To better understand these processes, scientists have used many tools to assess the contribution of individual anti-apoptotic BCL-2 family members. This review will focus on the prominent roles for BCL-2 and other pro-survival family members in promoting the development of mammals during early embryogenesis, neurogenesis, and hematopoiesis.Cell Death and Differentiation advance online publication, 3 November 2017; doi:10.1038/cdd.2017.170.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher
[do] DOI:10.1038/cdd.2017.170

  3 / 263942 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29099480
[Au] Autor:Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
[Ti] Title:Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
[So] Source:Blood Cancer J;7(11):e620, 2017 Nov 03.
[Is] ISSN:2044-5385
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:This corrects the article DOI: 10.1038/bcj.2015.86.
[Pt] Publication type:PUBLISHED ERRATUM
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:In-Data-Review
[do] DOI:10.1038/bcj.2017.100

  4 / 263942 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Vargas, Pablo Agustin
Lopes, Márcio Ajudarte

[PMID]: 29099369
[Au] Autor:Miranda Galvis M; Reis LAD; Santos-Silva AR; Vargas PA; Corrêa MB; Lopes MA
[Ti] Title:Hodgkin lymphoma diagnosed during dental treatment: the importance of neck palpation.
[So] Source:Gen Dent;65(6):65-68, 2017 Nov-Dec.
[Is] ISSN:0363-6771
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Hodgkin lymphoma (HL) is a malignant lymphoproliferative disease that originates from alterations in germinal center B cells. HL generally affects cervical and supraclavicular nodes, and the most common clinical presentation is adenopathy. It can be symptomatic and detected by the patient or asymptomatic and identified during a physical examination. This article reports the case of a 17-year-old girl who was diagnosed with HL during dental treatment, highlighting the importance of a complete physical examination in dental practice.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:In-Process

  5 / 263942 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29098990
[Au] Autor:Sharma P; Goyal S; Yadav AK; Singh J; Mandal AK
[Ad] Address:Department of Pathology, Vardhman Mahavir Medical College, Safdarjung Hospital, New Delhi, India.
[Ti] Title:Hodgkin's lymphoma arising in a case of mycosis fungoides: An unusual association.
[So] Source:Indian J Dermatol Venereol Leprol;, 2017 Nov 03.
[Is] ISSN:0973-3922
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:Mycosis fungoides is a cutaneous T-cell lymphoma with a high risk for developing secondary malignancies, especially B-cell lymphoproliferative disorders. About 40 cases of Hodgkin's lymphoma associated with mycosis fungoides have been reported in literature till date. We report a case of a 35-year-old gentleman who presented with intensely itchy reddish lesions all over the body. Multiple skin biopsies taken from the lesions on scalp and back confirmed the clinical diagnosis of mycosis fungoides. While on treatment, he presented with multiple bilateral cervical, axillary and inguinal lymphadenopathy 9 years after the primary diagnosis of mycosis fungoides. Excision biopsy of a cervical lymph node revealed partial effacement of architecture by a tumor comprising polymorphous background. Histopathology and immunohistochemistry revealed a diagnosis of Hodgkin's lymphoma - nodular sclerosis subtype. The patient was started on chemotherapy for stage IV Hodgkin's lymphoma. Our case emphasizes the importance of keeping secondary Hodgkin's lymphoma in mind while dealing with a patient of mycosis fungoides. Our case immunohistochemically supports the distinct etiopathogenesis of Epstein-Barr virus-negative Hodgkin's lymphoma vis-à-vis cutaneous mycosis fungoides.
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher
[do] DOI:10.4103/ijdvl.IJDVL_744_16

  6 / 263942 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29098723
[Au] Autor:Wang Y; Revollo J; McKinzie P; Pearce MG; Dad A; Yucesoy B; Rosenfeldt H; Heflich RH; Dobrovolsky VN
[Ad] Address:Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas.
[Ti] Title:Establishing a novel Pig-a gene mutation assay in L5178YTk mouse lymphoma cells.
[So] Source:Environ Mol Mutagen;, 2017 Nov 02.
[Is] ISSN:1098-2280
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The X-linked Pig-a gene encodes an enzyme required for the biosynthesis of glycosyl phosphatidylinositol (GPI) anchors. Pig-a mutant cells fail to synthesize GPI and to express GPI-anchored protein markers (e.g., CD90) on their surface. Marker deficiency serves as a phenotypic indicator of Pig-a mutation in various in vivo assays. Here, we describe an in vitro Pig-a mutation assay in L5178YTk mouse lymphoma cells, in which mutant-phenotype cells are measured by flow cytometry using a fluorescent anti-CD90 antibody. Increased frequencies of CD90-deficient mutants were detected in cells treated with benzo[a]pyrene (B[a]P), N-ethyl-N-nitrosourea (ENU), ethyl methanesulphonate, and 7,12-dimethylbenz[a]anthracene, with near maximum mutant frequencies measured eight days after treatment. The CD90 deficiency in mutant cells quantified by flow cytometry was shown to be due to loss of GPI anchors in a limiting-dilution cloning assay using proaerolysin selection. Individual CD90-deficient cells from cultures treated with ENU, B[a]P, and vehicle were sorted and clonally expanded for molecular analysis of their Pig-a gene. Pig-a mutations with agent-specific signatures were found in nearly all clones that developed from sorted CD90-deficient cells. These results indicate that a Pig-a mutation assay can be successfully conducted in L5178YTk cells. The assay may be useful for mutagenicity screening of environmental agents as well as for testing hypotheses in vitro before committing to in vivo Pig-a assays. Environ. Mol. Mutagen., 2017. Published 2017. This article is a US Government work and is in the public domain in the USA.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher
[do] DOI:10.1002/em.22152

  7 / 263942 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29097924
[Au] Autor:Deng S; Wu Z; Wu Y; Zhang W; Li J; Dai N; Zhang B; Yan J
[Ad] Address:Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
[Ti] Title:Meta-Analysis of the Correlation between Apparent Diffusion Coefficient and Standardized Uptake Value in Malignant Disease.
[So] Source:Contrast Media Mol Imaging;2017:4729547, 2017.
[Is] ISSN:1555-4317
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The objective of this meta-analysis is to explore the correlation between the apparent diffusion coefficient (ADC) on diffusion-weighted MR and the standard uptake value (SUV) of F-FDG on PET/CT in patients with cancer. Databases such as PubMed (MEDLINE included), EMBASE, and Cochrane Database of Systematic Review were searched for relevant original articles that explored the correlation between SUV and ADC in English. After applying Fisher's -to- transformation, correlation coefficient ( ) values were extracted from each study and 95% confidence intervals (CIs) were calculated. Sensitivity and subgroup analyses based on tumor type were performed to investigate the potential heterogeneity. Forty-nine studies were eligible for the meta-analysis, comprising 1927 patients. Pooled for all studies was -0.35 (95% CI: -0.42-0.28) and exhibited a notable heterogeneity ( = 78.4%; < 0.01). In terms of the cancer type subgroup analysis, combined correlation coefficients of ADC/SUV range from -0.12 (lymphoma, = 5) to -0.59 (pancreatic cancer, = 2). We concluded that there is an average negative correlation between ADC and SUV in patients with cancer. Higher correlations were found in the brain tumor, cervix carcinoma, and pancreas cancer. However, a larger, prospective study is warranted to validate these findings in different cancer types.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:In-Process
[do] DOI:10.1155/2017/4729547

  8 / 263942 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29097683
[Au] Autor:Borchmann S; Müller H; Engert A
[Ad] Address:German Hodgkin Study Group (GHSG), Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany. sven.borchmann@uk-koeln.de.
[Ti] Title:Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude.
[So] Source:Sci Rep;7(1):14903, 2017 Nov 02.
[Is] ISSN:2045-2322
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Seasonal variations in incidence and mortality after a Hodgkin lymphoma (HL) diagnosis have been previously described with partly conflicting results. The goal of this analysis is to provide a comprehensive analysis of these seasonal variations. In total, 41,405 HL cases diagnosed between 1973 and 2012 in the 18 Surveillance, Epidemiology, and End Results registries were included. Cosinor analysis and Cox proportional-hazards models were employed to analyze seasonality of incidence and mortality, respectively. HL shows a sinusoid seasonal incidence pattern (p < 0.001). Estimated incidence in March is 15.4% [95%-CI: 10.8-20.0] higher than in September. This sinusoid pattern is more pronounced at higher latitudes (p = 0.023). The risk of dying within the first three years after a HL diagnosis in winter is significantly increased compared to a HL diagnosis in summer at higher latitudes (HR = 1.082 [95%-CI: 1.009-1.161], p = 0.027). Furthermore, increasing northern latitude increases the additional mortality risk conferred by a diagnosis in winter (p 0.033). The seasonality patterns presented here provide epidemiological evidence that Vitamin D might play a protective role in HL. Further evidence on the direct association between Vitamin D levels and the clinical course of HL needs to be collected to advance the understanding of the role of Vitamin D in HL.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:In-Data-Review
[do] DOI:10.1038/s41598-017-14805-y

  9 / 263942 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29097500
[Au] Autor:Bosch M; Akhter A; Chen BE; Mansoor A; Lebrun D; Good D; Crump M; Shepherd L; Scott DW; Stewart DA; Canadian Cancer Trials Group
[Ad] Address:University of Saskatchewan, Saskatoon, Canada.
[Ti] Title:A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
[So] Source:Haematologica;, 2017 Nov 02.
[Is] ISSN:1592-8721
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:The objective of this study was to create a bio-clinical model, based on clinical and molecular predictors of event-free and overall survival for relapsed/refractory diffuse large B-cell lymphoma patients treated on the Canadian Cancer Trials Group LY12 prospective study. Sufficient histologic material was available for 91 cases to create tissue microarrays and perform immunohistochemistry staining for CD10, BCL6, MUM1/IRF4, FOXP1, LMO2, BCL2, MYC, P53 and pySTAT3 expression. 67 cases had material sufficient for fluorescent in-situ hybridization for MYC and BCL2. In addition, 97 formalin-fixed, paraffin-embedded tissue samples underwent digital gene expression profiling to evaluate BCL2, MYC, P53, and STAT3 expression, and to determine Cell-of-Origin using the Lymph2Cx assay. No method of determining Cell-of Origin predicted event-free or overall survival. Factors independently associated with survival outcomes in multivariate analysis included primary refractory disease, elevated serum LDH at relapse, and MYC or BCL2 protein or gene expression. A bio-clinical score using these 4 factors predicted outcome with 3-year event-free survival for cases with 0-1 vs 2-4 factors of 55% vs 16% (p<0.0001) respectively, for assessing MYC and BCL2 by immunohistochemistry, and 46% vs 5% (p<0.0001) assessing MYC and BCL2 mRNA by digital gene expression, and 42% vs 21% (p=0.079) assessing MYC and BCL2 by fluorescent in-situ hybridization. This proposed bio-clinical model should be further studied and validated in other datasets, but may discriminate relapsed/refractory DLBCL patients who could benefit from conventional salvage therapy from others who require novel approaches. The LY12 study was registered at ClinicalTrials.gov: NCT00078949.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher

  10 / 263942 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29097495
[Au] Autor:Ng SB; Chung TH; Kato S; Nakamura S; Takahashi E; Ko YH; Khoury JD; Yin CC; Soong R; Jeyasekharan AD; Hoppe MM; Selvarajan V; Tan SY; Lim ST; Ong CK; Nairismägi ML; Maheshwari P; Choo SN; Fan S; Lee CK; Chuang SS; Chng WJ
[Ad] Address:Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore; patnsb@nus.edu.sg.
[Ti] Title:EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes.
[So] Source:Haematologica;, 2017 Nov 02.
[Is] ISSN:1592-8721
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:The molecular biology of primary nodal T- and NK-cell lymphoma and its relationsihp with extranodal NK/T-cell lymphoma, nasal type is poorly understood. In this study, we assessed the relationship between nodal and extranodal EBV-positive T/NK-cell lymphomas using gene expression profiling and copy number aberration analyses. We performed GEP and CNA analysis on 66 cases of EBV-associated T/NK-cell lymphoma from nodal and extranodal sites, and correlated the molecular signatures with clinicopathologic features. Three distinct molecular clusters were identified with one enriched for nodal presentation and loss of 14q11.2 (TCRA loci). TNKL with nodal presentation (N-group) was significantly associated with older age, lack of nasal involvement, and T-cell lineage compared to those with extranodal presentation (EN-group). On multivariate analysis, nodal presentation was an independent factor associated with short survival. The molecular signature of N-group compared to EN-group was characterized by upregulation of PD-L1 and T-cell related genes, including CD2 and CD8, and downregulation of CD56, consistent with the CD8+/CD56- immunophenotype. PD-L1 and CD2 protein expression levels were validated using multiplexed immunofluorescence. Interestingly, N-group was associated with 14q11.2 loss which correlated with loss of TCR loci and T-cell origin. Overall, our results suggest that TNKL with nodal presentation is distinct and deserves to be classified separately from those with extranodal presentation. Upregulation of PD-L1 indicates the possibility of anti-PD1 immunotherapy in this distinctive entity. In addition, loss of 14q11.2 may be a potentially useful diagnostic marker of T-cell lineage.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher


page 1 of 26395 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information